Pancreatic Cancer Research Results and Study Updates
See Advances in Pancreatic Cancer Research for an overview of recent findings and progress, plus ongoing projects supported by NCI.
Boosting Dendritic Cells Helps the Immune System Find Pancreatic CancerPosted:
The number of dendritic cells in a tumor may explain why immunotherapies work for some cancers but not others, a new study suggests. In mice, boosting dendritic cells triggered an immune response that slowed pancreatic tumor growth.
To Treat Pancreatic Cancer, Mouse Study Suggests Altering Tumor MicrobiomePosted:
In people with pancreatic cancer, the makeup of bacteria that populate their tumors could predict how long they live, results from a new study suggest. Experiments in mice suggested that altering the tumor microbiome could play a role in treatment.
Trial Highlights Complexities of Targeted Therapy for Pancreatic CancerPosted:
Olaparib (Lynparza) may be beneficial for some people with advanced pancreatic cancer who have inherited mutations in the BRCA1 or BRCA2 genes, according to results from the POLO trial.
Researchers Discover Potential Way to Hit Elusive Target in Pancreatic CancerPosted:
Three research groups have found a potential way to kill cancer cells in pancreatic tumors by simultaneously blocking the activity of proteins that interact with KRAS proteins and disrupting an energy-creating process called autophagy.
Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic CancerPosted:
Results from two clinical trials are expected to improve the outlook for some people with early-stage pancreatic cancer. Altering the chemotherapy drugs used and the timing of treatment substantially improved survival.
FDA Approves New Treatment for Certain Neuroendocrine TumorsPosted:
People with cancerous neuroendocrine tumors (NETs) that affect the digestive tract now have a new treatment option. On January 29, FDA approved the targeted treatment lutetium Lu 177 dotatate (Lutathera®) for adult patients with advanced NETs that affect the pancreas or gastrointestinal tract.
Dual-Biomarker Blood Test Shows Promise for Pancreatic Cancer Early DetectionPosted:
A new blood test that measures levels of two specific proteins may be able to accurately detect pancreatic cancer at its earliest stages, when it is most likely to respond to treatment, findings from a new study suggest.
Targeted Therapies Sunitinib and Everolimus Improve Survival for Patients with Rare Type of Pancreatic CancerUpdated:
In 2011, based on initial findings from two clinical trials, the Food and Drug Administration approved sunitinib and everolimus for patients with pancreatic neuroendocrine tumors. Updated results from the everolimus trial were published in September 2016.
Pancreatic Cancer Cells May Obtain Nutrients from Neighboring CellsPosted:
Pancreatic cancer cells instruct healthy cells around them to provide nutrients they need to survive and grow, a new study suggests.
Crosstalk between Cancer Cells and Neighboring Cells May Contribute to Tumor GrowthPosted:
Pancreatic cancer cells and neighboring normal cells engage in a two-way molecular conversation that helps drive malignant behavior in the cancer cells, according to new study results.
FDA Approves Irinotecan Liposome to Treat Pancreatic CancerPosted:
Patients with metastatic pancreatic cancer that has progressed after receiving gemcitabine-based chemotherapy now have a new treatment option: irinotecan liposome in combination with fluorouracil and leucovorin.
Pancreatic Cancer Study Finds Possible Diagnostic Marker in BloodPosted:
A protein attached to vesicles circulating in the blood could be a biological marker for detecting early signs of pancreatic cancer.
Combination of Nab-Paclitaxel and Gemcitabine Improves Survival in Patients with Metastatic Pancreatic CancerPosted:
In an international randomized phase III trial, patients with metastatic pancreatic cancer who were treated with a combination of albumin-bound paclitaxel (nab-paclitaxel [Abraxane®]) and gemcitabine (Gemzar®) lived longer than patients who were treated with gemcitabine alone. Patients who received both drugs also lived longer without their disease getting worse (progression-free survival).